Related Experiment Video
Updated: Jul 7, 2026

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier
Published on: November 12, 2013
Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke
Chelsea S Kidwell1, Larry Latour, Jeffrey L Saver
1Department of Neurology, Georgetown University, Washington, DC 20010, USA. ck256@georgetown.edu
Background:
In experimental models of cerebral ischemia, thrombolytic drugs have been demonstrated to have a number of neurovascular toxic effects including blood brain barrier disruption. Early barrier opening caused by focal cerebral ischemia in human stroke can be assessed by the presence of gadolinium enhancement of cerebrospinal fluid, termed 'Hyperintense Acute Injury Marker' (HARM).
Methods:
In a retrospective analysis, the frequency of HARM was studied in 140 patients, 38 receiving intra-arterial thrombolytics, 18 undergoing mechanical embolectomy, 24 receiving intravenous tissue plasminogen activator and 60 patients receiving no acute intervention.
Results:
HARM was found in 66% of patients undergoing intra-arterial thrombolysis and 50% of patients receiving intravenous tissue plasminogen activator, compared to 28% of patients undergoing mechanical embolectomy and 30% of patients receiving no acute therapy (p = 0.002). Both thrombolytic therapy (p = 0.001) and age (p = 0.001) were independent predictors of HARM. HARM was an independent predictor of hemorrhagic transformation (p = 0.007).
Conclusions:
This is the first study in humans providing supportive evidence of the neurovascular toxic effects of thrombolytics and suggests that HARM may be used as a biomarker of blood brain barrier disruption in future research of acute stroke therapies.
Related Concept Videos
Ischemic Stroke ll: Pathophysiology
The Blood-brain Barrier
Hemorrhagic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction
Ischemic Stroke l: Introduction
Hemorrhagic Stroke l: Introduction

